度普利尤单抗对瘙痒性皮肤病的效果及对嗜酸粒细胞恢复和生活质量的影响

doi:10.3969/j.issn.1000-8535.2023.06.013

摘要/Abstract

摘要： 目的探讨度普利尤单抗对瘙痒性皮肤病的效果及对嗜酸粒细胞（EOS）恢复和生活质量的影响。方法选取2021年2月—2022年1月期间,我院收治的瘙痒性皮肤病患者96例。根据治疗方式不同分为对照组（48例）和观察组（48例）。对照组给予传统激素治疗,观察组给予度普利尤单抗治疗。比较治疗前后2组血清炎症因子、免疫球蛋白水平情况;比较治疗前后2组症状积分下降指数（SSRI 评分）、神经激肽/速激肽受体1（NK1R）及EOS情况。观察2组疗效情况。采用皮肤病生活质量问卷（DLQI）对2组生活质量进行评价,并观察2组复发率情况。结果治疗后,2组血清IFN-γ（干扰素-γ）、IL-2（白介素2）、IgA、IgG、IgM、NK1R、EOS水平升高,IL-4、IL-13、IgE水平及SSRI 评分降低,且观察组更明显（P<0.05）。观察组治疗有效率高于对照组（P<0.05）。随访6个月,观察组DLQI评分及复发率低于对照组（P<0.05）。结论度普利尤单抗可减轻瘙痒性皮肤病患者瘙痒症状,增强机体防御力,促进嗜酸粒细胞恢复,提高其生活质量,值得临床推广应用。

关键词: 度普利尤单抗, 瘙痒性皮肤病, 免疫球蛋白能, 嗜酸粒细胞, 生活质量

Abstract: Objective To investigate the effect of Dupilumab on pruritic dermatosis,eosinophil（EOS）recovery and quality of life．Methods From February 2021 to January 2022,96 patients with pruritic dermatosis were selected．According to different treatment methods,they were divided into control group（48 cases）and observation group（48 cases）．The control group was treated with traditional hormone,and the observation group was treated with Dupilumab．The levels of serum inflammatory factors and immunoglobulin in the two groups were compared before and after treatment．The symptom score reduce index（SSRI score）,neurokinin/tachykinin receptor 1（NK1R）and EOS were compared between the two groups before and after treatment．The curative effect of the two groups was observed．The quality of life of the two groups was evaluated with Dermatology Quality of Life Questionnaire（DLQI）,and the recurrence rate of the two groups was observed．Results After treatment,levels of serum IFN-γ,IL-2,IgA,IgG,IgM,NK1R and EOS of two groups increased,while the levels of IL-4,IL-13,IgE and SSRI scores decreased,especially in the observation group（P<0.05）．The effective rate of the observation group was higher than that of the control group（P<0.05）．The DLQI score and recurrence rate in the observation group were lower than those in the control group（P<0.05）in 6 months follow-up．Conclusions Dupilumab can alleviate the itching symptoms of patients with pruritic dermatosis,enhance the body's defense,promote eosinophil recovery,and improve their quality of life,which is worthy of clinical application．

Key words: Dupilumab, itching dermatosis, immunoglobulin energy, eosinophils, quality of life

邱媛媛, 邹玲, 向叶, 刘启亮. 度普利尤单抗对瘙痒性皮肤病的效果及对嗜酸粒细胞恢复和生活质量的影响[J]. 广州医药, 2023, 54(6): 74-77.

QIU Yuanyuan, ZOU Ling, XIANG Ye, LIU Qiliang. Effect of Dupilumab on pruritic dermatosis,eosinophil recovery and quality of life[J]. Guangzhou Medical Journal, 2023, 54(6): 74-77.

参考文献

[1] KATOH N,OHYA Y,IKEDA M,et al.Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018,The Japanese Society of Allergology,The Japanese Dermatology Association.Japanese guidelines for atopic dermatitis 2020[J].Allergol Int,2020,69(3):356-369.
[2] 鲁瑾,杨慧,汤璐瑜.贵阳市15家养老机构老年瘙痒性皮肤病发病情况及生活质量[J].中国老年学杂志,2020,40(16):3564-3567.
[3] REICH K,KABASHIMA K,PERIS K,et al.Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis:A randomized clinical trial[J].JAMA Dermatol,2020,156(12):1333-1343.
[4] 卢娇. 强脉冲光联合成纤维细胞生长因子治疗激素依赖性皮炎患者经皮水分丢失量的效果研究[J].中国处方药,2022,20(8):142-144.
[5] 顾建青,高翔,孙劲旅,等.度普利尤单抗治疗中重度特应性皮炎初步临床观察[J].中华临床免疫和变态反应杂志,2021,15(4):370-375.
[6] 李妍,徐薇,顾恒,等.阿伐斯汀联合氯雷他定治疗慢性难治性荨麻疹的多中心随机对照研究[J].中华皮肤科杂志,2020,53(5):319-323.
[7] SAJEDIANFARD S,HANDJANI F,SAKI N,et al.Family dermatology life quality index in patients with pemphigus vulgaris:A cross-sectional study[J].Indian J Dermatol Venereol Leprol,2021,87(3):375-378.
[8] 陆晓云,张曾云鸥,肖风丽.上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用[J].中华皮肤科杂志,2022,55(6):548-551.
[9] SIEGELS D,HERATIZADEH A,ABRAHAM S,et al.Systemic treatments in the management of atopic dermatitis:A systematic review and meta-analysis[J].Allergy,2021,76(4):1053-1076.
[10] REICH K,TEIXEIRA H D,de BRUIN-WELLER M,et al.Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis(AD Up):results from a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2021,397(10290):2169-2181.
[11] ZENG Z W,HUANG J Q,CHEN Y,et al.Acupoint autohemotherapy attenuates atopic dermatitis lesions by regulating Th1/Th2 balance in DNCB-induced BALB/c mice[J].Chin J Integr Med,2022,28(7):612-619.
[12] 刘燕婷,李晓强,陈乐,等.白芨散治疗脂溢性皮炎临床观察及对血清IL-4、IL-6、INF-γ水平的影响[J].湖北中医药大学学报,2022,24(1):82-84.
[13] 姜静婧,宋红梅.IgE介导的自身免疫及炎症反应的研究进展[J].国际儿科学杂志,2021,48(11):780-784.
[14] 刘钧菲,刘翠华,厉洪江,等.白芍总苷胶囊联合注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗幼年特发性关节炎23例及对T淋巴细胞免疫、Th1/Th2漂移及红细胞沉降率的影响[J].安徽医药,2020,24(2):381-385.
[15] 潘展砚,金城,董达科.外周血嗜酸性粒细胞计数在急性荨麻疹住院患者中的临床意义[J].检验医学与临床,2021,18(15):2169-2172.
[16] HENDRICKS A J,YOSIPOVITCH G,SHI V Y.Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review[J].J Dermatolog Treat,2021,32(1):19-28.